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Abstract: Magnetic nanoparticles have been largely applied to increase the efficacy of antibiotics
due to passive accumulation provided by enhancing permeability and retention, which is essential
for the treatment of lung infections. Recurring lung infections such as in the life-shortening genetic
disease cystic fibrosis (CF) are a major problem. The recent advent of the CF modulator drug ivacaftor,
alone or in combination with lumacaftor or tezacaftor, has enabled systemic treatment of the majority
of patients. Magnetic nanoparticles (MNPs) show unique properties such as biocompatibility
and biodegradability as well as magnetic and heat-medicated characteristics. These properties
make them suitable to be used as drug carriers and hyperthermia-based agents. Hyperthermia is
a promising approach for the thermal activation therapy of several diseases, including pulmonary
diseases. The benefits of delivering CF drugs via inhalation using MNPs as drug carriers afford
application of sufficient therapeutic dosages directly to the primary target site, while avoiding
potential suboptimal pharmacokinetics/pharmacodynamics and minimizing the risks of systemic
toxicity. This review explores the multidisciplinary approach of using MNPs as vehicles of drug
delivery. Additionally, we highlight advantages such as increased drug concentration at disease site,
minimized drug loss and the possibility of specific cell targeting, while addressing major challenges
for this emerging field.
Keywords: cystic fibrosis; magnetic nanoparticles; ivacaftor; CFTR modulator; gene therapy;
pulmonary; non-viral gene delivery
1. Introduction
Inhalation of medications for respiratory diseases such as cystic fibrosis, asthma or chronic
obstructive pulmonary disease (COPD) play a pivotal role in the prophylaxis and treatment of these
common respiratory diseases. The most effective treatments involve aerosolised drug administration
delivering corticosteroids in asthma or COPD, or antibiotics in lung infections directly to the respiratory
tract, thereby achieving sufficient drug concentrations. A major advantage in delivering drugs directly
to the lung is that aerosolised administration significantly decreases potential toxicity associated with
systemic exposure (Figure 1).
Ultrasonic systems, jet systems, and other systems using a vibrating mesh/aperture plate are
employed as the primary tools for aerosolised pulmonary delivery of drugs via nebulization [1].
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Figure 1. Schematic overview of pharmacokinetics of inhaled drugs. 
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1.1.1. An Introduction to the Disease 
Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene. CF is the most common genetic disease 
in Caucasian populations [2]. To date, more than 2000 CFTR protein mutations have been identified 
and categorised into six functional classes I to VI, based on different underlying mutations and 
disease outcomes (Table 1)[3]. CFTR is a transmembrane protein that is expressed at high levels on 
apical membrane epithelial cells and regulates the transport of ions such as sodium, chloride and 
bicarbonate[4]. This disease affects exocrine mucus glands of the lung, pancreas, liver and intestines 
and is characterised by progressive lung disease and pancreatic insufficiency[3]. Dysfunction in the 
CFTR results in impaired chloride ion secretion, hyperabsorption of sodium ions and subsequent 
production of mucus that is thick, viscous and difficult to clear[3]. This is particularly problematic in 
the respiratory tract where the production of viscous mucus causes a reduction in mucociliary 
clearance and initiates a vicious cycle of recurrent and persistent bacterial infections[5,6]. These 
conditions result in a vicious cycle ofpulmonary exacerbations, predisposing CF patients to 
progressive loss of lung function, respiratory failure and consequently death[7]. 
1.1.2. Current Treatments 
Conventional existing CF treatments have predominantly been symptomatic therapy focused 
on attenuating disease progression and maintaining lung function[5,8]. Antibiotics and anti-
inflammatory drugs are administered to control bacterial infections and inflammation[5,8], while 
bronchodilators, mucolytics and osmotic agents are administered to remove mucus and clear 
airways[9]. More recently, a large focus has been placed on CFTR modulators designed to target 
certain biological consequences that are characteristic of CFTR mutation classes or correct specific 
CFTR gene mutations, and these are discussed below. 
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1.1. Cystic Fibrosis
1.1.1. An Introduct on to he Diseas
Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene. CF is the most common genetic disease
in Caucasian populations [2]. To date, more than 2000 CFTR protein mutations have been identified
and categorised into six functional classes I to VI, based on different underlying mutations and disease
outcomes (Table 1) [3]. CFTR is a transmembrane protein that is expressed at high levels on apical
membrane epithelial cells and regulates the transport of ions such as sodiu , chloride and bicarbonate [4].
This disease affects exocrine mucus glands of the lung, pancreas, liver and intestines and is characterised
by progressive lung disease and pancreatic insufficiency [3]. Dysfunction in the CFTR results in impaired
chloride ion secretion, hyperabsorption of sodium ions and subsequent production of mucus that is
thick, viscous and difficult to clear [3]. This is particularly problematic in the respiratory tract where
the production of viscous mucus causes a reduction in mucociliary clearance and initiates a vicious
cycle of recurrent and persistent bacterial infections [5,6]. These conditions result in a vicious cycle of
pulmonary exacerbations, predisposing CF patients to progressive loss of lung function, respiratory
failure and consequently death [7].
1.1.2. Current Treatments
Conventional existing CF treatments have predominantly been symptomatic therapy focused on
attenuating disease progression and maintaining lung function [5,8]. Antibiotics and anti-inflammatory
drugs are administered to control bacterial infections and inflammation [5,8], while bronchodilators,
mucolytics and osmotic agents are administered to remove mucus and clear airways [9]. More recently,
a large focus has been placed on CFTR modulators designed o target certain biological consequences
that ar characteristic of CFTR mutation classes or correct specific CFTR gene mutations, and these are
discussed below.
CFTR Modulators
Since the development of CFTR modulators, these small therapy treatments have significantly
improved the quality of life for CF patients with specific CFTR mutations, namely ivacaftor, lumacaftor,
tezacaftor and, recently, elexacaftor. Ivacaftor is the first FDA (Food and Drug Administration
)-approved CFTR potentiator drug that addresses the specific G551D gating mutation (class III mutation,
affects 4%–6% of CF population) [10]. Ivacaftor monotherapy was later approved for use of additional
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gating mutations [11]. In 2015, the FDA approved the first combination formulation, combining ivacaftor
with the first CFTR corrector, lumacaftor [10]. Subsequently, tezacaftor, a second-generation corrector,
gained approval for combination use with the potentiator ivacaftor [12]. This dual combination
approach of combining a CFTR corrector, which rescues F508del CFTR to the cell surface, with a CFTR
potentiator that potentiates CFTR channel activity, effectively expands the treatment window to
the majority of CF; however, some mutations like nonsense mutations remain unrescuable with CFTR
modulator treatment [13]. Effort continues to be put into developing next-generation potentiators
and correctors with the aim to offer treatment options for all patients with CF [14].
Antibiotics
An essential pillar of pulmonary treatment in CF is the use of antibiotics, which have led to
a significant improvement in prognosis since the 1960s [5]. In the CF airway, increased mucus viscosity
and impairment of mucociliary clearance promotes bacterial colonization of airways. The most common
airway pathogen in the adult CF population is Pseudomonas aeruginosa (P. aeruginosa), and colonisation
with P. aeruginosa is directly correlated with a decline in lung function [5]. Other CF relevant organisms
include Burkholderia cepacia as well as Haemophilus influenzae and Staphylococcus aureus, which are
more commonly found in paediatric CF cohorts [5,15]. Long-term maintenance therapy with inhaled
therapeutics is typically used to suppress infection, reduce pulmonary exacerbations and maintain
lung function once chronic P. aeruginosa infection occurs [5]. Traditionally, tobramycin, aztreonam
and colistin have been used for treatment of chronic P. aeruginosa infection in CF patients [5].
Tobramycin
Inhaled tobramycin solution (TIS) was the first aerosolised antibiotic to be approved and is
clinically available as a pre-mixed 300 mg/5 mL vial for use twice daily for cystic fibrosis patients [5,8].
Since then, new dry powder formulations have been developed and the approval of tobramycin
inhalation powder (TIP) was a breakthrough in inhalation therapy for CF. This dry powder formulation
has been shown to have a shorter administration time, increased patient adherence and overall
satisfaction than TIS [16,17]. Previous studies have shown improved delivery of tobramycin through
thick mucus and enhanced treatment of planktonic P. aeruginosa via conjugating its amino groups with
carboxyl groups of citric acid-coated magnetic nanoparticles [18,19].
Aztreonam
Aztreonam is a monocylic β-lactams antibiotic used via intravenous (i.v.) formulation for
decades against Gram-negative bacteria [20]. Notably, several side effects including rash, nausea,
vomiting and diarrhea have been reported in patients with CF [20]. A potential explanation is that
the i.v. formulation contains arginine salt known to cause bronchoconstriction and induce airway
inflammation [8,20]. Subsequently, arginine salt has since been substituted with lysine to allow
an aerosolised application with less side effects [20].
Colistinmethate Sodium
Colistin, also known as polymyxin E, is a last-line antibiotic against Gram-negative pathogens
and in CF, and is used for treatment of chronic endobronchial P. aeruginosa infection [21]. Historically,
colistin has been administered intravenously; however, its use has declined due to neurotoxicity
and nephrotoxicity, in addition to less toxic alternatives, e.g., tobramycin [8]. The resurrection of colistin
in recent times has been led by the lack of effective treatment options against multi-drug resistant
pathogens in addition to the development of newer and safer formulations [8]. In CF, the inactive
prodrug colistinmethate sodium (CMS) has been available to the clinic for decades [15,22].
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Mucolytics and Osmotic Agents
CFTR dysfunction results in thick viscous mucus that is difficult to clear resulting in recurring lung
infections [5]. Furthermore, increased neutrophil degeneration in CF releases large amounts of DNA
spiralling down the vicious cycle of further increasing mucus viscosity [23]. Two leading mucoactive
agents are N-acetyl cysteine (NAC) and recombinant human deoxyribonuclease I (rhDNase, also knows
as dornase alfa) [8,9]. NAC decreases mucus viscosity by disrupting disulphide bonds connecting
mucin proteins in mucus [8]. rhDNase enzymatically breaks down DNA in airway secretions, reducing
the size of DNA released in sputum [8].
Another therapeutic approach to aid rehydration of airway surfaces and sputum clearance is
the use of inhaled hypertonic saline [23]. Beneficially, inhaled hypertonic saline was found to also
improve lung function and reduce the number of pulmonary exacerbations [24]. Unfortunately, the use
of a nebuliser has proven to be a major obstacle due to logistical difficulties in requiring an electrical
supply element, as well as thorough cleaning and disinfection procedures after each single use [25].
1.2. Magnetic Nanoparticles
The symbiotic marriage of targeted drug delivery with nanopharmacy has resulted in a number
of designs for nanoscale, making magnetic materials ideal for the application as drug delivery carriers
(Figure 2, Table 2) [26].
Due to low toxicity, the most commonly used magnetic nanoparticles (MNPs) employ
ferromagnetic elements, such as iron, nickel and cobalt, and their compounds, ferrites, magnetite
and maghemite [26]. The two main forms of FDA-approved compounds, maghemite (Fe2O3)
and magnetite (Fe3O4), can be easily synthesized with controlled size and shape [36,37]. In the past
decade, their application in the diagnosis and treatment of various diseases like cancer has grown
exponentially; importantly, they offer novel delivery options for respiratory diseases [38–40].
MNPs can be synthetised using a great variety of methods, with the most frequently used being
co-precipitation, high temperature decomposition of organic precursors, hydrothermal, microemulsions
and sol-gel polymerization [41]. They can be easily used as drug carriers since they can modulate
the release of different drugs by the application of different frequencies and intensities of an applied
external magnetic field. Furthermore, the magnetic properties of these MNPs influence the drug release
profile; for example, the specific absorption rate or the saturation of the magnetisation depending
on the morphology and anisotropy of the particles [42]. It has been demonstrated that, for example,
cubic or octopod iron oxide nanoparticles have superior magnetic heating efficiency as compared
to spherical particles of similar sizes [43]. The adsorption of these drugs could be using physical or
chemical methods; for example, physical encapsulation using ionic complexation, nanoprecipitation,
emulsions, gelations, etc.
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Table 1. Classification of cystic fibrosis transmembrane conductance regulator (CFTR) mutations and therapeutic strategies.
CFTR Class I II III IV V VI
CFTR defect Protein synthesis Maturation processing Ion channel gating Ion channel conductance Reduced protein Reduced membranestability











synthesis Impacted surface retention
Cellular compartment where








621 + 1G→T 1078delT;
1717-1G→A;
R560T, N1303K G85E, F508del,
I507del
G551S, G970R, G1244E,




2789 + 5G→A, 3849 +
10KbC→T
120del23, N287Y
Prevalence within CF cohort * 22% 88% 6% 6% 5% 0.5%
Patients with modulator
approved genotype <0.5% 39.2% 4.6% 2.6% 3.5% -





* People with cystic fibrosis (CF) can have more than one mutation. The percentage is representative of the entire population and does not add up to 100; adapted from [14,27,28].
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Table 2. Structure of CF therapies.
Name Mode of Action Structure Ref.
CFTR modulator
Ivacaftor Potentiator
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Table 2. Cont.
Name Mode of Action Structure Ref.
Inhaled Antibiotics
Levofloxacin Fluoroquinolone





























































































































































































































































































Figure 2. Magnetic nanoparticle coated with a surface coating and functional groups chosen for 
specific uses, e.g., targeting agents, permeation enhancers or fluorophores. 
Due to low toxicity, the most commonly used magnetic nanoparticles (MNPs) employ 
ferromagnetic elements, such as iron, nickel and cobalt, and their compounds, ferrites, magnetite and 
Figure 2. Magnetic nanoparticle coated with a surface coating and functional groups chosen for specific
uses, e.g., targeting agents, permeation enhancers or fluorophores.
MNPs can be used in hyperthermia as heat mediators, which can convert magnetic energy into
thermal energy under the influence of external magnetic field. In hyperthermia, upon applying
an external magnetic field, the alternative magnetic field (AMF) oscillates. This oscillation is faster
than the relaxation time of MNP and thus causes a delay of magnetic moment relaxation resulting in
the generation of heat. MNPs mediate heat via the relaxation losses which occur via Neel relaxation
and Brownian relaxation. The Neel relaxation is a result of reorientation of magnetic moment in
the same direction as the applied magnetic field, and it is size-dependent and prevails in small NPs
only. On the other hand, Brownian relaxation is a kind of friction force resulting from the rotation
of the NPs in the liquid suspension. Brownian relaxation is both size and viscosity dependent.
The amount of released heat is quantified via measuring the specific absorption rate (SAR) [26].
Intensive efforts have focused on developing optimised synthesis protocols for the obtaining of MNPs
with reproducible, uniform and well-defined sizes and shapes that also show superparamagnetic
behaviour. Superparamagnetism allows MNPs under the control of an external magnetic field to
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deliver the drug directly to a desired part of the lung while keeping healthy cells away from exposure.
In addition, the local hyperthermic effect of MNPs enables magnetically triggered drug release profiles.
Most importantly, MNPs play a vital role in the treatment of CF via acting as nano-knives, under
the effect of external magnetic field, which can penetrate the thick mucus and biofilm layers to allow
the exposure of micro-organisms and inflamed cells to the delivered drugs [44]. It is noteworthy
that MNPs can also be employed for other respiratory diseases. Tanmoy Sadhukha et al. (2013)
demonstrated that magnetic hyperthermia was particularly suitable for the treatment of lung cancer,
where the external AMF can be easily focused [45]. The relatively inert nature of magnetic substances
in the absence of magnetic fields and their efficacy in the presence of AMF make this technique highly
suitable for achieving an on-demand response. Furthermore, lungs are filled with air, which act as
a poor conductor of heat. Thus, the heat generated by the particles in the lungs is less likely to affect
the surrounding organs such as the heart. These authors described that instillation or inhalation of
iron magnetic nanoparticles results in an effective therapeutic magnetic hyperthermia treatment of
in vivo tumor growth in lungs, with minimal exposure to other organs [45].
To display optimal efficiency for biological application, colloidal suspensions of MNPs require
long-time stability in aqueous media as well as a magnetic core responsive to an external magnetic
field, allowing optimal formation.
1.3. Inhaled Therapeutics
As lung delivery presents itself as the major therapeutic target in CF, inhalation drug delivery
offers novel strategies for existing and emerging therapeutic agents [46]. Inhalation administration
allows the delivery of high drug doses directly to the site of action while minimising potential side
effects and risk of systemic toxicity [5,8]. Additional benefits include fast-acting and non-invasive
applications, high compliance and suitability for home therapy [8]. Although the benefits of inhalation
therapy are undeniable, the aforementioned lung delivery comes with indisputable drawbacks like
large variability in drug absorption, ambiguity regarding target specific concentrations as well as local
specific side effects including counterproductive chest tightness and wheezing [7,20]. Furthermore,
efficient inhalation delivery is hampered by difficulties in drug formulations including ideal particle
size and powder flowability [46].
Magnetic nanoparticles can be useful to overcome all these difficulties since aerosol deposition
can be magnetically targeted to a region of interest in the lung via the presence of a target-directed
external magnetic field. Using superparamagnetic iron oxide NPs (SPIONs) in aerosol droplets
(nanomagnetosol), where the SPIONs are physically connected by a solvent, was shown to increase
the magnetic moment and improve the magnetic targeting efficacy [47]. The combination of
the direct magnetic field with a simultaneous perpendicular, high frequency alternating magnetic field
induced vibrations that caused a local increase in temperature and facilitate NP transport through
the mucus. Magnetic hyperthermia was shown to be an effective method for decreasing the viscosity
of biofilms and mucus, as well as enhancing drug and immune cell penetration to the affected area.
Furthermore, bacterial growth is strongly temperature dependent, so hyperthermia can noticeably
reduce the formation and growth of biofilms. Therefore, the disruption of biofilms and the retardation of
S. aureus growth can be controlled by the surface coating of SPIONs, such as carboxylate functionalized
SPIONs [48].
Current devices for drug delivery via inhalation can be broadly categorized into, firstly, aerosols
delivered via nebulizers and, secondly, dry powders for inhalation delivered by dry powder inhalers
(DPIs). The characteristics of these devices are summarised in Table 3.
To combat chronic airway colonization of P. aeruginosa aggressively, diligent use of antibiotic
regimes to delay onset is key [20]. Hence, the treatment of chronic lung infection remains a major focus
of inhaled therapy in CF [30].
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Table 3. Characteristics of inhalation devices commonly used for pulmonary delivery.
Inhalation Device
Nebuliser Dry Powder Inhaler (DPI)
Mechanism Nebulisation by air-jet Dry powder
Characteristics Vibrating mesh technology or aerosoldroplets generated from liquids High stability and sterility
Advantages
Little training for correct use required
Ability to deliver large dosages









Use in children limited
Efficiency requires high
inspiratory effort
Optimal dosage requires proper
dose preparation and loading
Adapted from [49].
1.4. Approved Inhaled Antibiotics for the Treatment of Lung Infections in CF
An overview of approved inhalation treatment options for CF is summarized in Table 4.
Tobramycin (TIP) capsules formulated with low density porous particles have been shown to improve
flow and dispersion by inhalation [5]. To date, two phase III studies have investigated the efficacy
and safety of this novel and FDA-approved formulation. The EVOLVE study reported the efficacy
of TIP-formulated tobramycin in 95 patients over placebo, with significantly improved FEV1 (forced
expiratory volume in one second) during treatment for 84 days [50]. The larger scale EAGER study
of 553 patients compared the use of 3 treatment cycles of TIP (with TIS) and demonstrated similar
efficacy of microbial response with higher treatment satisfaction [17]. In both studies, no severe adverse
reactions were reported, with only cough being the most frequently reported adverse reaction related
to the dry powder. In this study, the authors concluded that the recommended dose for patients
with CF is 112 mg (four 28 mg capsules) inhaled twice daily with alternating 28 day on-treatment
and off-treatment cycles [5]. Notably, mild adverse reactions to inhaled tobramycin also include
tinnitus and hoarseness; however, prolonged exposure may result in a cumulative effect potentially
causing nephrotoxicity and ototoxicity [20].
More recently, lyophilized formulations which increase the product stability of dry powder
were developed for unstable antibiotics such as aztreonam and colistin. Aztreonam lysine (AZLI)
has been approved for use with a nebulizer [5,51]. It is available to CF patients of 6 years or older,
with the recommended dose of 75 mg inhaled thrice daily and with alternating 28 day on-treatment
and off-treatment cycles [5]. Importantly, inhaled aztreonam was shown to significantly improve lung
function, respiratory symptoms such as cough, sputum production and wheezing, as well as reducing
bacterial density in sputum by suppressing chronic P. aeruginosa infections (which has long term effects
on patient survival) [5].
Colistimethate sodium salt (CMS) has been approved as a dry powder formulation in Europe for
treatment of chronic P. aeruginosa infections in CF patients of 6 years and older. The recommended dose
is a 125 mg capsule taken twice daily, administered using a hand-held inhaler [52]. A phase III open-label
trial showed that colistimethate sodium DPI was well tolerated and effective [52]. Additionally, patients
reported several advantages of using the DPI formulation over the nebulised solution formulation
including shorter administration time and enhanced portability [8,52].
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Table 4. Inhaled therapies currently used for treatment of CF.
Inhaled Therapy Status Dosage Delivery Method Target Potential Side Effects Reference
Mucociliary clearance




Dry powder Thick viscous mucous Cough [53,54]
Hypertonic saline - 7% saline (active),twice daily Nebuliser
Increase hydration of
airway surface liquid Cough [24]
Anti-infective
























(approved for use in
Europe & Canada)
Phase III completed




















Tobramycin (TIP) FDA approved 112 mg, twice daily Dry powder
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1.5. Approved Inhaled Mucolytics and Osmotic Agents
Approved inhaled mucolytics and osmotic agents include inhaled mannitol and hypertonic saline
(Table 4). Inhaled mannitol administered as a dry powder formulation has been shown to hydrate
airway surfaces and additionally improve mucus clearance [25]. Two phase III studies reported
increase in FEV1, albeit no significant improvements were observed in children (6–11 years old) or
adolescents (12–17 years old). Furthermore, a 29% reduction of pulmonary exacerbation was reported
in patients given 400 mg of inhaled mannitol [53]. Additionally, sustained improvement in lung
function over 6 months indicates inhaled mannitol to be an important treatment for CF [53,54]. Inhaled
mannitol is administered as a 400 mg dose twice daily, dispensed with an inhaler using 10 individually
loaded capsules [53]. Despite no reports of serious respiratory events, patients suffered from cough
episodes which led 21.1% in the mannitol group and 16.7% in the control group to the discontinuation
of the treatment [53].
1.6. Inhaled Antibiotics in Clinical Trials
In CF, one of the major challenges is the need for alternative antibiotic options as inhaled
antibiotics such as tobramycin to be prescribed on an ‘on-off’ regimen (Table 4). The question of
what alternate antibiotic to then use can often be very challenging, highlighting the need for more
effect treatment options [58]. Fluoroquinolones have traditionally been used in CF due to their large
spectrum of bactericidal activity, rapid cellular uptake and excellent bioavailability and tolerance [8].
Inhaled fluoroquinolones, e.g., ciprofloxacin and levofloxacin, are currently in phase III clinical trials
(NCT01270347 and NCT01180634) to assess their effect as the second alternate antibiotic during “off”
cycles of TIS to avoid drug resistance and improve patient outcomes [8].
Ciprofloxacin is a second generation fluoroquinolone that has been reformulated as a dry powder
formulation with low density porous particles for the management of chronic P. aeruginosa infections
in CF patients [5]. Phase I studies in paediatric and adult CF patients using single and multiple dose
administration showed high concentrations in the lung were achieved with low systemic exposure [5].
A phase II study with the inhaled dry powder ciprofloxacin given at two doses (32.5 mg and 48.75 mg)
twice daily for 28 days showed a significant reduction in the density of P. aeruginosa when compared to
placebo [55]. Nevertheless, this effect was not sustained to the end of the study where the difference
was found to be not significant when compared to placebo [55]. Although a trend in improving
the quality of life was reported, the study failed to improve the primary endpoint FEV1. Furthermore,
no significant changes were reported for other endpoints such as respiratory symptoms or pulmonary
exacerbations [55]. A sunlight sensitivity rash, cartilage toxicity and the emergence of resistance
were some of the main side effects [8]. In contrast to the CF study, a separate phase II study using
ciprofloxacin DPI has demonstrated a positive effect in patients with bronchiectasis and is currently
undergoing phase III trials [58].
Recently, a magnetically triggered release method of ciprofloxacin has been obtained using
magnetic poly(lactic-co-glycolic) acid (PLGA) micro/NPs. The attained hyperthermic activity of
the developed MNPs upon applying AMF has enhanced the drug release. In particular, the obtained
results showed a twofold increase in ciprofloxacin release from MNPs-PLGA NPs as compared with
the nonmagnetic PLGA NPs [59].
A phase II study showed inhaled levofloxacin, a third generation fluoroquinolone, was well
tolerated, and a reduction in P. aeruginosa density and a dose-dependent increase in FEV1 was observed
(in 240 mg given twice daily group) when compared to placebo [60]. Further pharmacokinetic
studies highlighted low systemic exposure with high levels in sputum [60]. However, a randomised
phase III study with 335 participants given either inhaled levofloxacin (n = 220, solution) or placebo
(n = 110) did not demonstrate a clear benefit in reducing or delaying pulmonary exacerbations [56].
Treatment-related dysgeusia was reported in 35.2% of the inhaled levofloxacin group during treatment
duration, with other reported side effects in both treatment groups being cough, nausea, pyrexia
and haemoptysis [56]. Similar reasons such as disease progression and dysgeusia were reported for
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the discontinuation of the study in both groups [56]. Another phase III study comprising of 282
CF patients evaluated the safety and efficacy of inhaled levofloxacin (n = 189) to TIS (n = 93) [57].
Inhaled levofloxacin was well tolerated and demonstrated non-inferiority to TIS [57]. Treatment-related
side effects were reported by 22% of the inhaled levofloxacin group and 32.2% of the TIS group [57].
Discontinuation and occurrence of side effects were similar between both groups, with dysgeusia being
reported as the most frequent adverse event [57].
Taken together, new methods of drug delivery and technology are needed to address issues
of antibiotic resistance, adverse treatment-related side effects and improved therapeutics for
the CF population.
1.7. Gene Delivery
The successful cloning of the CFTR gene in 1989 marks a major breakthrough in the recent
development of gene therapy in cystic fibrosis [61–63]. Unfortunately, current efforts have only been
partially successful as, firstly, lung gene transfer proves to be inefficient and, secondly, a complete
understanding of gene transfer agents is crucial [64]. A major conceptual advantage of gene therapy
over small molecules such as CFTR modulators is that gene therapy could potentially treat all classes
of CF [12]. To date, the most challenging hurdle for CF gene therapy remains drug delivery.
1.7.1. Barriers to Gene Delivery
Lung delivery continues to prove a difficult target due to effective intra- and extracellular barriers
shielding the lung from inhaled material. Additionally, extracellular barriers include mucociliary
clearance and immune response mechanisms [65–68]. Amongst typical biological barriers to lung drug
delivery, the CF lung proves to be an added challenge in the form of a thick mucus layer blocking
access to epithelial lung cells.
1.7.2. Mucus-Penetrating Magnetic Nanoparticles (MNPs)
To date, one of the greatest challenges in treating CF with MNPs is the successful penetration
of the thick, sticky mucus that is characteristic of CF disease. The CF mucus architecture sterically
hinders drug delivery to the lung and reduces drug delivery efficacy [9]. Due to their small size,
MNPs have emerged as promising vehicles to package drugs and transport through the mucus,
with increasing penetration resulting in higher delivery rates. Magnetite (Fe3O4) is preferred over
maghemite (Fe2O3) as core material since Fe3+ is naturally internalized by many pathogenic bacteria
and triggers targeting [69]. One example is the study carried out by Scherer et al. (2002) that describes
the use of poly(ethylene imine)-coated MNPs as a gene vector [70]. The magnetic field was applied to
these MNPs in an in vitro study and showed a significant improvement in the rapid accumulation of
gene vector in the targeted cells.
The use of MNPs in combination with gene therapy also includes the attachment of
viruses to the surface of MNPs to enhance the transfection efficiency. Morishita et al. (2005)
attached HVJ-E virus loaded with the gene vector to the surface of protamine sulfate (PS)-coated
MNPs [71]. This study was implemented using the EGFP (Ehhanced Green Fluorescent Protein) gene
and FITC-oligodeoxynucleotide for baby hamster kidney cells and examined the luciferase gene in COS7
cells, obtaining a significant enhancement in the transfection efficiency in a dose-dependent manner.
In summary, the efficient penetration of MNPs into the mucus phase can be achieved by eliminating
potential electrostatic interactions of MNPs with mucus by coating MNPs with electrostatically neutral
molecules such as polyethylenglycol (PEG) or increasing mucus penetration by mucus-inert add-ons
or mycolytics attached to the MNP [72,73]. Notably, MNPs offer the potential to deliver not only
antibiotics directly to the lung, but also the aforementioned gene therapy approach. Suk et al.
(2011) compared the diffusivity, displacement and transport rates of uncoated NPs with PEGylated
NPs of 100, 200 and 500 nm [73]. The study concluded that coating of 200 nm PEGylation was
optimal in regard to mucus penetration compared with uncoated, smaller and larger coated NPs.
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The PEG chain conformation and resulting effect of PEGylation degree was further investigated by
Craparo et al. (2016), delivering nonsteroidal anti-inflammatory ibuprofen as a newly synthesised
mucus-penetrating fluorescent NP [74]. To form grafted co-polymers with an average NP size <200 nm,
the authors employed α,β-Poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA), thatwas covalently bound
to rhodamine B (RhB) and polylactic acid (PLA), and further coated with 0%, 2% or 8.5% PEGylation.
PEG density increases were reported to be directly correlated with increases of the penetrating ability
of PHEA-RhB-PLA-PEG NPs, suggesting the PEG chain to be an important property for the activity
of NPs.
Direct delivery of CFTR modulators to the lung offers potential benefits of correcting the CFTR
at a major target side or contributing to the eradication of lung infections [15,75]. Porsio et al. (2018)
developed an ~70 nm PEG-coated NP containing a transactivating transcriptional activator peptide
(Tat) that was loaded with ivacaftor [75]. The authors reported that faster penetration and higher
rates of ivacaftor release (12%) were achieved by their ivacaftor-loaded NP compared to free ivacaftor
(6% release). This approach offers great potential for delivering CFTR modulators directly to the lung,
although clinical trials are needed to confirm these findings in the clinic.
1.7.3. Non-Viral Vectors for Gene Delivery
For a comprehensive overview on viral vectors refer to the review by Griesenbach and Alton et al.
(2013) [62] and Schneider-Futschik (2019) [12]. Non-viral vectors such as NPs have the potential
to circumvent some of the viral vector-induced problems, such as limited packaging capacity or
immune response [76]. Non-viral approaches include cationic liposomes, DNA nanoparticles/polymers
and naked DNA. NPs can be developed with a variety of materials including several shapes and sizes,
different surface charges and with specific targeting moieties (Table 5). In the past, the aforementioned
mucolytics such as NAC and rhDNase were used to improve the delivery of non-viral gene carriers,
albeit with varying outcomes.
MNPs can be used to transfer different genes, providing protection and stability to DNA
and increasing the transformation efficiency and safety, namely magnetofection. The mechanism of
magnetofection is similar to using transfection reagents with the only difference that the plasmids form
complexes with cationic polymer-coated MNPs, for example poly(ethylenimine) (PEI)-coated MNPs [77].
Furthermore, MNPs display advantageous properties as they are not subjected to microbial interactions
due to the inorganic nature of the metallic core. In addition, these nanoparticles can be functionalised
with different functionalised groups, e.g., carboxyl, amines, biotin, polyethyleneimine and antibodies,
allowing several methods of DNA or RNA attachment and, furthermore, suitable delivery of small
interfering RNA or oligonucleotides under in vitro and in vivo conditions. One study carried out by
Tang et al. (2014) describes the preparation of magnetic calcium phosphate nano-formulations that
were used for transfection of DNA [78]. In the same way, any other divalent metal cations, such as
Mg+2, Mn+2 and Ba+2 can form ionic complexes with the DNA (similar to Ca+2), providing stabilization
to DNA structures.
Gold MNPs are very attractive as non-viral vectors due to their low chemical reactivity, stability
easy preparation and gene transfection efficacy. Likewise, SPIONS have been described as gene
delivery systems, especially as pulmonary gene delivery agents. Nguyen et al. (2009) described how
to prepare SPIONS coated with PEG or branched with biodegradable polyesthers that maintained
their transfection ability at in vivo condition after nebulization [79]. Furthermore, Dames et al. (2007)
described the preparation of SPIONs used as magnetic aerosol droplets for the treatment of lung
disorders such as cystic fibrosis and asthma [80]. Recent studies have combined MNP-heating
properties and MNP-transfection characteristics, in order to develop both a hyperthermia and gene
delivery system [81]. The development of a novel and synergic methodology of magnetofection using
oscillating MNPs is a future field to be explored.
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Table 5. Characteristics of magnetic nanoparticles (MNPs) for CF.


































Reference [73] [82] [83] [83] [82] [84] [82]
* PGLA = poly(lactic-co-glycolic acid); adapted from Ong et al. [9].
1.7.4. Clinical Trials in CF Using NPs
The UK Gene Therapy Consortium developed a cationic NP lipid formulation, namely, GL67A [85];
however, the immune-stimulatory CpG dinucleotides which caused mild flu-like symptoms have
since been removed [86]. The subsequent plasmid, pGM169, encompasses a novel regulatory
element, hCEFI, comprising of the elongation factor 1 α promotor coupled to the human CMV
enhancer [87]. In 2015, a phase I/IIa study showed acceptable safety and efficacy using nebulised
liposome-mediated gene therapy for CF patients [88]. Subsequently, a prolonged multi-dose study was
undertaken, administering either 5 mL of nebulised pGM169/GL67A or 0.9% saline every month for 12
months. The 140 patients were randomly assigned to receive a placebo (n = 62) or pGM169/GL67A
(n = 78) [89]. A modest, albeit significant, effect in the pGM169/GL67A group was observed at 12
months follow-up (3.7%, 95% CI 0.1–7.3; p = 0.046) which was linked to a stabilisation of lung function
in the pGM169/GL67A group. However, the study did not proceed to substantive phase III studies
despite reaching primary endpoints.
1.8. Future Directions
In the past decade, remarkable progress has been accomplished in the treating CF. CFTR modulation
has been demonstrated to be effective in increasing the quality of life and life expectancy in a select
number of patients. This review underscores the importance of the inhaled delivery of CF drugs to
improve the efficacy of current systemic treatments. The main advantage of inhalation use is high drug
exposure at the primary target site, while avoiding unfavourable pharmacokinetic/pharmacodynamic
interactions associated with systemic use, as well as reducing the risks of potential systemic toxicity.
Employing MNPs through lung delivery is a currently untapped therapeutic approach in CF modulator
administration. The application of MNPs in CF still needs more experimental and clinical studies to
introduce a superparamagnetism high enough to control drug delivery without the cytotoxic effects of
the metal oxides. Encouraging results in the application of MNPs for CF have established the potential
utility of new technologies for CFTR modulators, mucolytics or antibiotics. Proof-of-concept studies
of effective MNP lung delivery will pave the way for future CFTR inhalation strategies to improve
clinical outcomes in patients with CF, as well as comprehensive study of its pharmacokinetic
and pharmacodynamics. Furthermore, rigorous testing of toxicity related to MNPs on the lung
tissues is required. Therefore, more effort and work is still required to optimize the targeted delivery
of MNPs in CF.
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